They then stimulated PBMCs of healthy donors with peptides from Melan-A/MART-1, a melanoma-specific tumor antigen, with or without a therapeutic dose of imatinib, and showed that imatinib treatment expanded Melan-A-specific CD8+ T cells accompanied by the depletion of eTregs. The gene discussed is MLANA; the disease is neoplasm.